Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Three factors to unlock the value of AI for life sciences
Posted on May 1st, 2019 by Christy J. Wilson in Pharma R&D
Artificial Intelligence (AI) has been at the top of many boardroom agendas for the last several years, as execs try to integrate the technology. Recent RELX research found that, across all industries, 88 percent of senior executives believe AI will help their businesses be more competitive. In the life sciences, AI has the potential to scale the benefits of precision medicine or automated disease prediction to more patients across the world, and could generate more than $150 billion in savings for the healthcare industry by 2025.
(more…)Working together to get the best out of AI for all
Posted on April 16th, 2019 by Nicki Catchpole in Pharma R&D
Go to any conference these days and the number one buzzword is AI. However, despite all the excitement, AI is still talked about in fairly vague terms – with few people able to pin down exactly what they mean by AI. New research from some of my Elsevier colleagues examined this phenomenon.
(more…)Data-Driven Technologies are Shaking Up the Drug Development Process
Posted on March 15th, 2019 by Nicki Catchpole in Pharma R&D
For many, many years, the findings of scientific research were published in an always-growing collection of scientific journals that spun off into more and more specialized disciplines. Today’s scientists have to think far beyond scholarly journals subscriptions and wrestle instead with search strategies and informatics.
Three ways to reduce the cost of precision medicine
Posted on March 12th, 2019 by Nicki Catchpole in Pharma R&D
In December 2018, the FDA announced it has formally recognized a public database containing genomic information, a huge milestone in the evolving field of precision medicine. Now researchers can use this information to validate their tests instead of having to generate their own data.
(more…)
